Is neurohormonal activation deleterious to the long-term outcome of patients with congestive heart failure? II. Protagonist's viewpoint.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000818:Animals; D002395:Catecholamines / Q000097:blood; D006321:Heart / Q000503:physiopathology; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology*; D006801:Humans; D018377:Neurotransmitter Agents / Q000502:physiology*; D011379:Prognosis; D012084:Renin-Angiotensin System; D013564:Sympathetic Nervous System / Q000503:physiopathology
D000319:Adrenergic beta-Antagonists; D002395:Catecholamines; D018377:Neurotransmitter Agents